- Home
- ATRA vs IBIO Comparison
ATRA vs IBIO Comparison
Compare ATRA & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ATRA | IBIO |
|---|---|---|
| Founded | 2012 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.2M | 83.5M |
| IPO Year | 2014 | 2009 |
Fundamental Metrics
Financial Performance| Metric | ATRA | IBIO |
|---|---|---|
| Price | $9.70 | $1.26 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $5.00 | $4.75 |
| AVG Volume (30 Days) | 42.1K | ★ 547.7K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 122.52 | 81.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $120,772,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.92 | $0.77 |
| 52 Week High | $19.15 | $3.82 |
Technical Indicators
Market Signals| Indicator | ATRA | IBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 42.31 |
| Support Level | $8.98 | $1.21 |
| Resistance Level | $10.02 | $1.52 |
| Average True Range (ATR) | 0.69 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 34.26 | 45.00 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.